# Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia

> **NCT01727232** · — · COMPLETED · sponsor: **Henri Mondor University Hospital** · enrollment: 107 (actual)

## Conditions studied

- Primary Immune Thrombocytopenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01727232
- **Lead sponsor:** Henri Mondor University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-10
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2012-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01727232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01727232, "Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01727232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*